Pharmacokinetics of high-titer anti–SARS-CoV-2 human convalescent plasma in high-risk children

BACKGROUND: While most children who contract COVID-19 experience mild disease, high-risk children with underlying conditions may develop severe disease, requiring interventions. Kinetics of antibodies transferred via COVID-19 convalescent plasma early in disease have not been characterized. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Gordon, Oren, Brosnan, Mary Katherine, Yoon, Steve, Jung, Dawoon, Littlefield, Kirsten, Ganesan, Abhinaya, Caputo, Christopher A., Li, Maggie, Morgenlander, William R., Henson, Stephanie N., Ordonez, Alvaro A., De Jesus, Patricia, Tucker, Elizabeth W., Peart Akindele, Nadine, Ma, Zexu, Wilson, Jo, Ruiz-Bedoya, Camilo A., Younger, M. Elizabeth M., Bloch, Evan M., Shoham, Shmuel, Sullivan, David, Tobian, Aaron A.R., Cooke, Kenneth R., Larman, Ben, Gobburu, Jogarao V.S., Casadevall, Arturo, Pekosz, Andrew, Lederman, Howard M., Klein, Sabra L., Jain, Sanjay K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855821/
https://www.ncbi.nlm.nih.gov/pubmed/34855624
http://dx.doi.org/10.1172/jci.insight.151518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855821/
https://www.ncbi.nlm.nih.gov/pubmed/34855624
http://dx.doi.org/10.1172/jci.insight.151518

Ejemplares similares